The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4/D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent.

Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.

The present invention provides a method of detecting or measuring trans-Resveratrol (tRV) in a sample, comprising: contacting a sample to be tested with a antibody against tRV, or an antigen binding fragment of such an antibody; and detecting or measuring any tRV bound by the antibody or antibody fragment. The invention also provides an antibody against trans-Resveratrol.

Effective and economical compositions and methods are disclosed for the treatment, and prevention of diseases and disorders associated with inflammation and/or damage to the gastrointestinal tract, including environmental enteric dysfunction. Compositions are provided comprising a synergistic combination of colostrum, immune egg, and optionally one or more additional active agents.

The invention relates to novel compositions managing or inhibiting blood clotting and related uses.

The present invention provides a method of detecting or measuring trans-Resveratrol (tRV) in a sample, comprising: contacting a sample to be tested with an antibody against tRV, or an antigen binding fragment of such an antibody; and detecting or measuring any tRV bound by the antibody or antibody fragment. The invention also provides an antibody against trans-Resveratrol.

A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).

This disclosure describes, in one aspect, a method for identifying -glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble -glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble -glucan to bind to the immune cells, and detecting soluble -glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of -glucan, and co-administering to the subject a soluble -glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

Mono or bi-specific antibodies, antibody fragments, or fusion proteins thereof, are capable of binding to the VHL ligand degrading moiety (degron) of a proteolysis targeting chimera (PROTAC) and, optionally, to a target protein. Complexes (PAX) of such antibodies, antibody fragments, fusion proteins thereof, and PROTACS are also capable of. Methods for their production can be performed, and these antibodies have medical and non-medical uses.